UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2024

BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)

Delaware
 001-01136
22-0790350
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S Employer Identification No.)
Route 206 & Province Line Road,
Princeton, New Jersey, 08543
(Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: (609) 252-4621
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 Par Value
BMY
New York Stock Exchange
1.000% Notes due 2025
BMY25
New York Stock Exchange
1.750% Notes due 2035
BMY35
New York Stock Exchange
Celgene Contingent Value Rights
CELG RT
New York Stock Exchange
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(d)          On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024.  The size of the Board was increased to eleven, effective July 1, 2024, in connection with the election of Mr. McMullen.

Mr. McMullen is 63 years old and has more than 20 years of executive experience and leadership skills managing large businesses and global operations as well as a proven track record of delivering excellent shareholder returns. During his tenure as CEO, Mr. McMullen led Agilent Technologies, Inc.’s (“Agilent”) transformation into a market leading life-sciences and diagnostics company, nearly tripled its market capitalization, and drove a business and cultural transformation that led to significant improvements in growth and improved profitability.

Mr. McMullen previously served as President and Chief Executive Officer of Agilent from 2015-2024. He is currently serving as a senior advisor to Agilent and its new CEO until October 31, 2024.

Prior to becoming CEO, Mr. McMullen served as Chief Operating Officer from 2014-2015, President of Agilent’s Chemical Analysis Group from 2009-2014 and held roles of increasing responsibilities during 1992-2009, including as Vice President and General Manager of the Chemical Analysis Solutions Unit of the Life Sciences and Chemical Analysis Group and Country Manager for Agilent's China, Japan and Korea Life Sciences and Chemical Analysis Group. He began his career when he joined Agilent’s predecessor, Hewlett-Packard Co., in 1984 as a Financial Analyst. In addition, he currently serves on the board of directors of KLA Corporation and is a former director of Agilent and Coherent, Inc.

Mr. McMullen received his M.B.A. with honors from the University of Pennsylvania’s Wharton School of Business. He received his undergraduate degree, a Bachelor of Science with a double major in finance and economics, magna cum laude from the University of Delaware.

The Board has determined that Mr. McMullen is independent under the New York Stock Exchange Listing Standards and the independence standards adopted by the Board.  He will serve as a member of the Audit Committee, effective July 1, 2024.

There are no arrangements or understandings between Mr. McMullen and any other persons pursuant to which he was selected as a director.  There are no related party transactions between the Company and Mr. McMullen.

Mr. McMullen will receive compensation for his service on the Board in accordance with the Company’s standard compensatory arrangement for non-employee directors, including an annual retainer of $110,000 and an annual award of deferred share units valued at $210,000 on the date of grant.

A copy of the press release announcing the election of Mr. McMullen is attached to this report as Exhibit 99.1.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are furnished as part of this Current Report on Form 8-K:

Exhibit
No.
  
Description
     
 
Press release of Bristol-Myers Squibb Company dated June 18, 2024.
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
  
       
Dated: June 18, 2024
By:
/s/ Amy Fallone
  
 
Name:
Amy Fallone
  
 
Title:
Corporate Secretary
  


Exhibit 99.1


Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors

(Princeton, N.J., June 18, 2024) – Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024. Mr. McMullen will serve as a member of the Audit Committee of the Board of Directors.
 
“We are pleased to welcome Mr. Michael McMullen to our Board of Directors,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. “Mike's extensive experience in managing large businesses and global operations, combined with his proven track record of delivering excellent shareholder returns, will prove valuable as we continue to strengthen the company’s long-term growth profile, progress our pipeline, and prioritize opportunities where we see the highest return for our patients and shareholders.”
 
Mr. McMullen previously served as president and chief executive officer of Agilent Technologies, Inc. (“Agilent”) from 2015-2024. He brings to the Board more than 20 years of executive experience and leadership skills. During his tenure as CEO, Mr. McMullen led Agilent’s transformation into a market-leading life sciences and diagnostics company, nearly tripled its market capitalization, and drove a business and cultural transformation that led to significant improvements in growth and improved profitability. He is currently serving as a senior advisor to Agilent and its new CEO until October 31, 2024.
 
Prior to becoming CEO of Agilent, Mr. McMullen served as chief operating officer from 2014-2015, president of Agilent’s Chemical Analysis Group from 2009-2014 and held roles of increasing responsibilities during 1992-2009, including as vice president and general manager of the Chemical Analysis Solutions Unit of the Life Sciences and Chemical Analysis Group and country manager for Agilent's China, Japan and Korea Life Sciences and Chemical Analysis Group. Mr. McMullen began his career when he joined Agilent's predecessor, Hewlett-Packard Co., in 1984 as a financial analyst.
 
1
Mr. McMullen received his M.B.A. with honors from the University of Pennsylvania’s Wharton School of Business. He received his undergraduate degree, with a double major in finance and economics, magna cum laude from the University of Delaware. Mr. McMullen also serves on the board of directors of KLA Corporation and is a former director of Agilent and Coherent, Inc.
 
Theodore R. Samuels, the Board’s lead independent director, said: “Mike is an accomplished global executive whose transformational success is widely acknowledged by investors and industry experts. His global experience and inspirational leadership style will benefit the company and uniquely position the Board to support the company through its next chapter. We welcome Mike and look forward to his contributions.”
 
Mr. McMullen commented: “I am pleased to be joining the Board of Bristol Myers Squibb, a company known and respected for its long history of innovation and scientific discovery. It’s an exciting time at Bristol Myers Squibb and I look forward to joining my fellow directors and the management team in helping the company realize the promise of the compelling opportunities ahead.”
 
With the appointment of Mr. McMullen, effective July 1, 2024, the size of the Board will increase to 11. He will receive compensation in accordance with the company’s director compensation program. For more information about the Bristol Myers Squibb Board of Directors, click here.
 
About Bristol Myers Squibb Company
 
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X (formerly Twitter), YouTube, Facebook, and Instagram.
 
2
 corporatefinancial-news

###

For more information, contact:

Media:
media@bms.com

Investors:
investor.relations@bms.com


3
v3.24.1.1.u2
Document and Entity Information
Jun. 18, 2024
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 18, 2024
Entity File Number 001-01136
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Central Index Key 0000014272
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One Route 206 & Province Line Road
Entity Address, City or Town Princeton
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08543
City Area Code 609
Local Phone Number 252-4621
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY25
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY35
Security Exchange Name NYSE
Celgene Contingent Value Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Celgene Contingent Value Rights
Trading Symbol CELG RT
Security Exchange Name NYSE
Bristol Myers Squibb (PK) (USOTC:BMYMP)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Bristol Myers Squibb (PK) Charts.
Bristol Myers Squibb (PK) (USOTC:BMYMP)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Bristol Myers Squibb (PK) Charts.